High-protein yogurt brand Oikos is expanding beyond the dairy aisle with protein shakes geared to GLP-1 users, Danone North ...

A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...

The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds over 72 weeks, ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

Eli Lilly rose Friday after topping Wall Street's first-quarter expectations. Eli Lilly stock bounced back after tumbling Thursday after CVS' Caremark selected Novo Nordisk's Wegovy as its preferred ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

WeightWatchers has announced a new partnership with Eli Lilly's LillyDirect pharmacy provider, Gifthealth, to facilitate easier access to Zepbound® (tirzepatide) for its clinic members.

If you’re living with overweight or obesity and are interested in exploring Zepbound as a treatment option, consulting a healthcare professional for a comprehensive evaluation is crucial.